Teladoc Health (NYSE:TDOC) CEO Charles Divita III Sells 17,138 Shares of Stock

by · The Markets Daily

Teladoc Health, Inc. (NYSE:TDOC – Get Free Report) CEO Charles Divita III sold 17,138 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares in the company, valued at $1,533,904.68. This trade represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Teladoc Health Stock Up 0.1%

Shares of NYSE:TDOC opened at $7.63 on Friday. The firm has a market capitalization of $1.35 billion, a PE ratio of -5.96 and a beta of 2.04. The business has a 50 day simple moving average of $7.97 and a two-hundred day simple moving average of $7.78. Teladoc Health, Inc. has a 1 year low of $6.35 and a 1 year high of $15.21. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60.

Teladoc Health (NYSE:TDOC – Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.05. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The firm had revenue of $626.44 million during the quarter, compared to analyst estimates of $625.66 million. During the same period last year, the company earned ($0.19) EPS. Teladoc Health’s quarterly revenue was down 2.2% compared to the same quarter last year. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. On average, equities analysts predict that Teladoc Health, Inc. will post -1.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on TDOC shares. Bank of America lowered their target price on shares of Teladoc Health from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, November 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a research report on Monday. Evercore ISI dropped their target price on shares of Teladoc Health from $9.00 to $8.00 and set an “in-line” rating on the stock in a research note on Thursday, October 30th. Citigroup lifted their price target on shares of Teladoc Health from $9.50 to $10.50 and gave the company a “neutral” rating in a research note on Tuesday, October 21st. Finally, Barclays initiated coverage on Teladoc Health in a research note on Tuesday. They issued an “equal weight” rating and a $8.50 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $9.60.

Read Our Latest Stock Report on TDOC

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Teladoc Health by 4.2% during the third quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after acquiring an additional 891,732 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Teladoc Health by 23.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock worth $53,260,000 after buying an additional 1,325,106 shares during the last quarter. Geode Capital Management LLC increased its position in Teladoc Health by 2.1% during the 2nd quarter. Geode Capital Management LLC now owns 4,150,197 shares of the health services provider’s stock valued at $36,153,000 after buying an additional 84,356 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Teladoc Health by 5.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,571,673 shares of the health services provider’s stock valued at $20,471,000 after buying an additional 127,960 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Teladoc Health by 11.1% in the third quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock valued at $17,661,000 after buying an additional 227,385 shares during the last quarter. Hedge funds and other institutional investors own 76.82% of the company’s stock.

About Teladoc Health

(Get Free Report)

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

See Also